ALLECRA THERAPS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALLECRA THERAPS, and when can generic versions of ALLECRA THERAPS drugs launch?
ALLECRA THERAPS has one approved drug.
There are two US patents protecting ALLECRA THERAPS drugs.
There are twenty-one patent family members on ALLECRA THERAPS drugs in eighteen countries.
Summary for ALLECRA THERAPS
| International Patents: | 21 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for ALLECRA THERAPS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allecra Theraps | EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165-001 | Feb 22, 2024 | DISCN | Yes | No | 11,124,526 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Allecra Theraps | EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165-001 | Feb 22, 2024 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Allecra Theraps | EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165-001 | Feb 22, 2024 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Allecra Theraps | EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165-001 | Feb 22, 2024 | DISCN | Yes | No | 7,687,488 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
